Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 383 full-time employees. The company went IPO on 2019-05-31. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The firm is also engaged in the transfer of intellectual property. The firm mainly conducts its business in the domestic market.
02181.HK stock price ended at $0.51 on 水曜日, after rising 2.00%
On the latest trading day Feb 11, 2026, the stock price of 02181.HK rose by 2.00%, climbing from $0.49 to $0.51. During the session, the stock saw a volatility of 4.08%, with prices oscillating between a daily low of $0.49 and a high of $0.51. Notably, trading volume dropped by 18.0K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 18.0K shares were traded, equating to a market value of approximately $2.1B.